好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Feasibility of Using Blood-based Biomarkers to Evaluate the Effectiveness of Individualized Neurodegenerative Disease Preventive Care
Aging, Dementia, and Behavioral Neurology
P4 - Poster Session 4 (11:45 AM-12:45 PM)
9-002
Establish biorepository of blood-based biomarkers for neurodegenerative diseases (ND); assess feasibility of biomarker collection/processing in subjects at risk for dementia; incorporate concurrent phenotypic clinical data; and explore utility of blood-based biomarkers as outcome measures for n-of-1 trials.
ND have an extended preclinical period. Early identification and intervention prior to dementia may offer the best opportunity to prevent or delay cognitive decline. Research suggests that blood-based biomarkers may be a reliable predictor of disease progression. The opportunity to use blood-based biomarkers to identify risk, monitor progression, and potentially guide individualized care represents a significant opportunity.
Subjects with family history of ND with no or minimal cognitive and/or neurological complaints were recruited. Demographics, medical history, cognitive assessments and blood-based biomarkers for ND (via venipuncture and/or at-home finger prick card testing) were collected at baseline and longitudinally. Blood-based biomarkers included: Amyloid beta 42/40 ratio, pTau181, pTau231, pTau217, Neurofilament light and glial fibrillary acidic protein. Subjects may also opt-in to share relevant data from preventive clinical care.
53 subjects (66% male, mean age 57.2, range 22-93, 62% ApoE4+) were enrolled. 75% of eligible subjects returned for follow-up assessments. A majority of subjects provided clinical data with biomarkers measured before and after risk reduction interventions prescribed by their physicians. Individualized clinical management consisted of various pharmacological therapies to address modifiable risk factors (e.g., tirzepatide, rosuvastatin, escitalopram), anti-amyloid therapies (e.g., aducanumab, lecanemab), other agents (e.g., rapamycin) and multi-modal lifestyle interventions (e.g., exercise, diet).
In subjects at risk for dementia, it was feasible to collect/process blood-biomarkers. Several subjects had measurable changes in biomarkers of ND pathology and/or improvements or stabilization of cognition. Further research using blood-based biomarkers to evaluate the effectiveness of individualized ND preventive care in real-world clinical settings is needed.
Authors/Disclosures
Philip E. Sisser
PRESENTER 		Mr. Sisser has received personal compensation for serving as an employee of PAREF.
Kellyann Niotis, MD Dr. Niotis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with PAREF.
Alon Seifan, MD (Cognitive Neurology Consultants, Inc. dba the Neuro Well) Dr. Seifan has received personal compensation in the range of $100,000-$499,999 for serving as a Chief Science Officer with HB Biotech.
Shannon Helfman Shannon Helfman has received personal compensation for serving as an employee of Institute for Neurodegenerative Diseases.
Praveen Parthasarathy Praveen Parthasarathy has nothing to disclose.
Hollie Hristov, NP (Atria Institute) Mrs. Hristov has nothing to disclose.
Juan Melendez-Herencia Juan Melendez-Herencia has nothing to disclose.
Helena Colvee (IND Florida) Helena Colvee has nothing to disclose.
Jessica Lakis (IND Florida) Jessica Lakis has nothing to disclose.
Christopher Janney (The Institute for Neurodegenerative Diseases (IND) Florida) Christopher Janney has received personal compensation for serving as an employee of Parkinson's Research & 好色先生 Foundation, Institute for Neurodegenerative Diseases. Christopher Janney has received intellectual property interests from a discovery or technology relating to health care.
Kiarra Akiyoshi Kiarra Akiyoshi has nothing to disclose.
Hanna Huber (University Gothenburg, Neurochemistry) No disclosure on file
Nicholas Ashton (University of Gothenburg) No disclosure on file
Henrik Zetterberg (Sahlgrenska University Hospital/Molndal) Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave. Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD. Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley and Elsevier. Henrik Zetterberg has stock in Brain Biomarker Solutions.
Richard S. Isaacson, MD, FAAN Dr. Isaacson has stock in Retain Health. The institution of Dr. Isaacson has received research support from National Institutes of Health. The institution of Dr. Isaacson has received research support from Aces for Alzheimer's. The institution of Dr. Isaacson has received research support from BrainMind. Dr. Isaacson has received publishing royalties from a publication relating to health care.